Keywords:
Connective tissue disorders, Treatment effects, Diagnostic procedure, CT, Lung
Authors:
M. Lacroix1, J. S. Rech2, C. DE MARGERIE-MELLON1, H. Nunes 2, Y. Uzunhan2, B. Arnulf1, P.-Y. Brillet3; 1Paris/FR, 2Bobigny /FR, 3Bobigny/FR
DOI:
10.26044/esti2019/P-0076
References
1. 1.
Mahmood S,
Bridoux F,
Venner CP,
Sachchithanantham S,
Gilbertson JA,
Rowczenio D,
et al.
Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.
Lancet Haematol.
2015;2
2. 2.
Baumgart J-V,
Stuhlmann-Laeisz C,
Hegenbart U,
Nattenmüller J,
Schönland S,
Krüger S,
et al.
Local vs.
systemic pulmonary amyloidosis—impact on diagnostics and clinical management.
Virchows Arch [Internet].
22 août 2018 [cité 7 sept 2018].
3. 3.
Khoor A,
Colby TV.
Amyloidosis of the Lung.
Arch Pathol Lab Med.
févr 2017;141(2):247‑54.
4. 4.
Milani P,
Basset M,
Russo F,
Foli A,
Palladini G,
Merlini G.
The lung in amyloidosis.
Eur Respir Rev Off J Eur Respir Soc.
30 sept 2017;26(145).
5. 5.
Utz JP,
Swensen SJ,
Gertz MA.
Pulmonary amyloidosis.
The Mayo Clinic experience from 1980 to 1993.
Ann Intern Med.
15 févr 1996;124(4):407‑13.